Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach

Background: Current combination treatments with direct-acting antiviral agents (DAAs) can cure more than 95% of hepatitis C virus (HCV) infections. However, resistance-associated substitutions (RASs) may emerge and can also be present in treatment-naïve patients. Methods, results and discussion: In...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Akaberi, Dario (VerfasserIn) , Bergfors, Assar (VerfasserIn) , Kjellin, Midori (VerfasserIn) , Kameli, Nader (VerfasserIn) , Lidemalm, Louise (VerfasserIn) , Kolli, Bhavya (VerfasserIn) , Shafer, Robert W. (VerfasserIn) , Palanisamy, Navaneethan (VerfasserIn) , Lennerstrand, Johan (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 13 September 2018
In: Infection ecology & epidemiology
Year: 2018, Jahrgang: 8
ISSN:2000-8686
DOI:10.1080/20008686.2018.1528117
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1080/20008686.2018.1528117
Volltext
Verfasserangaben:Dario Akaberi, Assar Bergfors, Midori Kjellin, Nader Kameli, Louise Lidemalm, Bhavya Kolli, Robert W. Shafer, Navaneethan Palanisamy and Johan Lennerstrand

MARC

LEADER 00000caa a2200000 c 4500
001 1696855195
003 DE-627
005 20230427121931.0
007 cr uuu---uuuuu
008 200429s2018 xx |||||o 00| ||eng c
024 7 |a 10.1080/20008686.2018.1528117  |2 doi 
035 |a (DE-627)1696855195 
035 |a (DE-599)KXP1696855195 
035 |a (OCoLC)1341317557 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Akaberi, Dario  |e VerfasserIn  |0 (DE-588)1160217742  |0 (DE-627)102335330X  |0 (DE-576)505603020  |4 aut 
245 1 0 |a Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach  |c Dario Akaberi, Assar Bergfors, Midori Kjellin, Nader Kameli, Louise Lidemalm, Bhavya Kolli, Robert W. Shafer, Navaneethan Palanisamy and Johan Lennerstrand 
264 1 |c 13 September 2018 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 29.04.2020 
520 |a Background: Current combination treatments with direct-acting antiviral agents (DAAs) can cure more than 95% of hepatitis C virus (HCV) infections. However, resistance-associated substitutions (RASs) may emerge and can also be present in treatment-naïve patients. Methods, results and discussion: In this study, a semi-pan-genotypic population sequencing method was developed and used to assess all NS5B amino acid variants between residue positions 310 and 564. Our method successfully sequenced more than 90% of genotype (GT) 1a, 1b, 2b and 3a samples. By using the population sequencing method with a cut-off of 20%, we found the dasabuvir RASs A553V and C445F to be a baseline polymorphism of GT 2b (8 out of 8) and GT 3a (18 out of 18) sequences, respectively. In GT 1a and 1b treatment-naïve subjects (n=25), no high-fold resistance polymorphism/RASs were identified. We further predicted dasabuvir’s binding pose with the NS5B polymerase using the in silico methods to elucidate the reasons associated with the resistance of clinically relevant RASs. Dasabuvir was docked at the palm-I site and was found to form hydrogen bonds with the residues S288, I447, Y448, N291 and D318. The RAS positions 316, 414, 448, 553 and 556 were found to constitute the dasabuvir binding pocket. 
650 4 |a dasabuvir 
650 4 |a Hepatitis C virus (HCV) 
650 4 |a in silico docking 
650 4 |a molecular dynamics (MD) simulation 
650 4 |a resistance 
700 1 |a Bergfors, Assar  |e VerfasserIn  |4 aut 
700 1 |a Kjellin, Midori  |e VerfasserIn  |4 aut 
700 1 |a Kameli, Nader  |e VerfasserIn  |4 aut 
700 1 |a Lidemalm, Louise  |e VerfasserIn  |4 aut 
700 1 |a Kolli, Bhavya  |e VerfasserIn  |4 aut 
700 1 |a Shafer, Robert W.  |e VerfasserIn  |4 aut 
700 1 |a Palanisamy, Navaneethan  |d 1989-  |e VerfasserIn  |0 (DE-588)1160214964  |0 (DE-627)102334727X  |0 (DE-576)505563193  |4 aut 
700 1 |a Lennerstrand, Johan  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Infection ecology & epidemiology  |d [Erscheinungsort nicht ermittelbar] : Co-Action Publ., 2011  |g 8(2018) Article: 1528117, 10 Seiten  |h Online-Ressource  |w (DE-627)668312076  |w (DE-600)2627673-2  |w (DE-576)350326673  |x 2000-8686  |7 nnas  |a Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach 
773 1 8 |g volume:8  |g year:2018  |g extent:10  |a Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach 
856 4 0 |u https://doi.org/10.1080/20008686.2018.1528117  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200429 
993 |a Article 
994 |a 2018 
998 |g 1160214964  |a Palanisamy, Navaneethan  |m 1160214964:Palanisamy, Navaneethan  |p 8 
999 |a KXP-PPN1696855195  |e 3643557132 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Dario Akaberi, Assar Bergfors, Midori Kjellin, Nader Kameli, Louise Lidemalm, Bhavya Kolli, Robert W. Shafer, Navaneethan Palanisamy and Johan Lennerstrand"]},"id":{"eki":["1696855195"],"doi":["10.1080/20008686.2018.1528117"]},"origin":[{"dateIssuedDisp":"13 September 2018","dateIssuedKey":"2018"}],"relHost":[{"title":[{"title_sort":"Infection ecology & epidemiology","title":"Infection ecology & epidemiology"}],"part":{"extent":"10","volume":"8","text":"8(2018) Article: 1528117, 10 Seiten","year":"2018"},"titleAlt":[{"title":"IEE"},{"title":"Infection ecology and epidemiology"}],"pubHistory":["1.2011 -"],"language":["eng"],"recId":"668312076","type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approachInfection ecology & epidemiology","note":["Gesehen am 20.12.17"],"id":{"eki":["668312076"],"zdb":["2627673-2"],"issn":["2000-8686"]},"origin":[{"publisherPlace":"[Erscheinungsort nicht ermittelbar]","dateIssuedKey":"2011","publisher":"Co-Action Publ.","dateIssuedDisp":"2011-"}],"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"10 S."}],"person":[{"roleDisplay":"VerfasserIn","display":"Akaberi, Dario","role":"aut","family":"Akaberi","given":"Dario"},{"family":"Bergfors","given":"Assar","display":"Bergfors, Assar","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Kjellin","given":"Midori","display":"Kjellin, Midori","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Kameli","given":"Nader","roleDisplay":"VerfasserIn","display":"Kameli, Nader","role":"aut"},{"family":"Lidemalm","given":"Louise","roleDisplay":"VerfasserIn","display":"Lidemalm, Louise","role":"aut"},{"role":"aut","display":"Kolli, Bhavya","roleDisplay":"VerfasserIn","given":"Bhavya","family":"Kolli"},{"given":"Robert W.","family":"Shafer","role":"aut","display":"Shafer, Robert W.","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Palanisamy, Navaneethan","roleDisplay":"VerfasserIn","given":"Navaneethan","family":"Palanisamy"},{"family":"Lennerstrand","given":"Johan","display":"Lennerstrand, Johan","roleDisplay":"VerfasserIn","role":"aut"}],"title":[{"title":"Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach","title_sort":"Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach"}],"language":["eng"],"recId":"1696855195","type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 29.04.2020"]} 
SRT |a AKABERIDARBASELINEDA1320